Citius Oncology, Inc. (CTOR): Total Liabilities
$56.08M
As of 2025-09-30
$71.71M
As of 2026-06-30
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-09-30 | $56.08M | +46.7% | 2025-12-23, Balance as of period end |
| 2024-09-30 | $38.23M | +72.2% | 2025-12-23, Balance as of period end |
| 2023-09-30 | $22.20M | n/a | 2024-12-27, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Citius Oncology, Inc. (CTOR) | 2025-09-30 | $56.08M | +46.7% |
| iBio, Inc. (IBIO) | 2026-06-30 | $13.40M | +61.3% |
| Minerva Neurosciences, Inc. (NERV) | 2025-12-31 | $233.76M | +272.0% |
| Tenax Therapeutics, Inc. (TENX) | 2025-12-31 | $7.16M | +52.5% |
| Immix Biopharma, Inc. (IMMX) | 2025-12-31 | $11.04M | +13.9% |
| Celularity Inc (CELU) | 2025-12-31 | $145.39M | +17.4% |
| Arbutus Biopharma Corp (ABUS) | 2025-12-31 | $18.04M | -47.5% |
| Journey Medical Corp (DERM) | 2025-12-31 | $62.74M | +4.3% |
| Relmada Therapeutics, Inc. (RLMD) | 2025-12-31 | $7.49M | -27.2% |
Compare CTOR, IBIO, NERV, TENX side by side · Screen every company in Pharmaceutical Preparations ↗